Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

AFFiRiS AG, corporate

AFFiRiS AG,

10.01.2020 - 10:02:16

AFFiRiS announces Phase 2 study in Parkinson's and new focus on neurodegenerative diseases

W www.affiris.com

Media Contact: MC Services AG Julia Hofmann P +49 89 210228 0 E affiris@mc-services.eu

Supplementary information:

About AFFiRiSwww.affiris.comLinkedIn

About SAIThttps://affiris.com/approach/#overview-of-sait

About neurodegenerative diseaseshttps://affiris.com/neurodegenerative-diseases/

About Parkinson's diseasehttps://affiris.com/neurodegenerative-diseases/#parkinsons-disease

10.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

950581  10.01.2020 

@ dgap.de